HK1252803A1 - 5-位修飾的嘧啶及它們的用途 - Google Patents

5-位修飾的嘧啶及它們的用途

Info

Publication number
HK1252803A1
HK1252803A1 HK18112104.8A HK18112104A HK1252803A1 HK 1252803 A1 HK1252803 A1 HK 1252803A1 HK 18112104 A HK18112104 A HK 18112104A HK 1252803 A1 HK1252803 A1 HK 1252803A1
Authority
HK
Hong Kong
Prior art keywords
pyramidines
modified
Prior art date
Application number
HK18112104.8A
Other languages
English (en)
Inventor
John ROHLOFF
Nebojsa Janjic
Jeffrey D Carter
Catherine Fowler
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US32314510P priority Critical
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of HK1252803A1 publication Critical patent/HK1252803A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/335Modified T or U
HK18112104.8A 2010-04-12 2018-09-20 5-位修飾的嘧啶及它們的用途 HK1252803A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US32314510P true 2010-04-12 2010-04-12

Publications (1)

Publication Number Publication Date
HK1252803A1 true HK1252803A1 (zh) 2019-06-06

Family

ID=44798979

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102316.6A HK1201740A1 (zh) 2010-04-12 2015-03-06 β- β- 針對β- 的適體及其在治療β- 介導的疾病和失調中的用途
HK18112104.8A HK1252803A1 (zh) 2010-04-12 2018-09-20 5-位修飾的嘧啶及它們的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15102316.6A HK1201740A1 (zh) 2010-04-12 2015-03-06 β- β- 針對β- 的適體及其在治療β- 介導的疾病和失調中的用途

Country Status (23)

Country Link
US (7) US8598140B2 (zh)
EP (3) EP3345915A1 (zh)
JP (4) JP5901610B2 (zh)
KR (4) KR20130043099A (zh)
CN (4) CN102985435B (zh)
AR (1) AR081452A1 (zh)
AU (2) AU2011240677B2 (zh)
BR (1) BR112012025872A2 (zh)
CA (3) CA2797188C (zh)
CO (1) CO6630139A2 (zh)
DK (1) DK2558478T3 (zh)
EA (1) EA022429B1 (zh)
ES (2) ES2667491T3 (zh)
HK (2) HK1201740A1 (zh)
IL (5) IL222339A (zh)
MX (2) MX2012011771A (zh)
MY (1) MY160608A (zh)
NO (1) NO2558478T3 (zh)
NZ (1) NZ602618A (zh)
SG (3) SG2014006522A (zh)
TW (6) TWI505833B (zh)
UA (1) UA105290C2 (zh)
WO (2) WO2011130289A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0151312B2 (zh) * 1982-11-17 1989-11-02 Fujitsu Ltd
US20110136099A1 (en) * 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
SG2014006522A (en) * 2010-04-12 2014-03-28 Somalogic Inc 5-position modified pyrimidines and their use
EP2635681B8 (en) 2010-11-05 2017-10-04 Miragen Therapeutics, Inc. Base modified oligonucleotides
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ngf組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
CN104379764B (zh) 2012-03-28 2018-04-06 私募蛋白质体公司 Pdgf和vegf的适体及它们在治疗pdgf和vegf介导的病状中的用途
US20140155411A1 (en) 2012-04-13 2014-06-05 Somalogic, Inc. Tuberculosis Biomarkers and Uses Thereof
EP2868747B1 (en) * 2012-07-02 2018-04-04 UNIST (Ulsan National Institute of Science and Technology) Aptamer for periostin and anti-cancer composition including same
JP6404822B2 (ja) 2012-10-23 2018-10-17 カリス ライフ サイエンシズ スウィッツァーランド ホールディングス ゲーエムベーハー アプタマーおよびその使用
CA2895847C (en) 2012-12-19 2019-01-08 Caris Science, Inc. Compositions and methods for aptamer screening
CA2902186A1 (en) 2013-03-14 2014-10-02 Somalogic, Inc. Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2014177510A2 (en) * 2013-05-03 2014-11-06 Creabilis Sa Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
CA2920508A1 (en) 2013-09-09 2015-03-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
SG11201602063UA (en) * 2013-09-24 2016-04-28 Somalogic Inc Multiaptamer target detection
JP2015062365A (ja) * 2013-09-25 2015-04-09 Necソリューションイノベータ株式会社 ラクトパミンに結合する核酸分子およびその用途
JP2015062364A (ja) * 2013-09-25 2015-04-09 Necソリューションイノベータ株式会社 クレンブテロールに結合する核酸分子およびその用途
WO2015066001A1 (en) * 2013-10-29 2015-05-07 Albert Einstein College Of Medicine Of Yeshiva University Nucleic acid-scaffolded small molecule libraries
CA2928207A1 (en) * 2013-11-21 2015-05-28 Somalogic, Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
EP3124611B1 (en) * 2014-03-24 2019-11-06 Ribomic Inc. Aptamer for fgf2 and use thereof
NO2718257T3 (zh) * 2014-05-30 2018-04-14
CN104561013A (zh) * 2015-01-05 2015-04-29 中国人民解放军南京军区福州总医院 基于高通量测序技术进行核酸适配体序列优化的方法
US10588900B2 (en) 2016-02-09 2020-03-17 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CN107663220A (zh) * 2016-07-27 2018-02-06 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
CA3041451A1 (en) 2016-10-24 2018-05-03 Biois Co.,Ltd Tnf-.alpha.-binding aptamer, and therapeutic use for same

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5599720A (en) 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3329892A1 (de) 1983-08-18 1985-03-07 Hubert Prof Dr Koester Verfahren zur herstellung von oligonucleotiden
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
DE3546807C2 (zh) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4752566A (en) 1985-12-17 1988-06-21 Genetics Institute, Inc. Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US4997818A (en) 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
WO1990015065A1 (en) * 1989-06-05 1990-12-13 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides and methods for preparing the same
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
AT139255T (de) 1989-10-24 1996-06-15 Gilead Sciences Inc Oligonukleotidanaloga mit neuartigen bindungen
WO1991013900A1 (en) 1990-03-13 1991-09-19 Acic (Canada) Inc. Process for producing 2,2'-o-cyclonucleosides, nucleosides, and analogs thereof
EP0537299A1 (en) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
AT160821T (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
AU1456092A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
WO1992014843A1 (en) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP0637965B1 (en) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
WO1997015691A1 (en) 1995-10-27 1997-05-01 Ramberg Elliot R Methods and compositions for detection of specific nucleotide sequences
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3485023B2 (ja) * 1999-05-20 2004-01-13 東亞合成株式会社 ヌクレオシド化合物
CN100457118C (zh) * 2000-04-13 2009-02-04 法玛塞特有限公司 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
WO2003031591A2 (en) 2001-10-10 2003-04-17 Superarray Bioscience Corporation Detecting targets by unique identifier nucleotide tags
CA2476309A1 (en) 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
JP3978187B2 (ja) 2002-03-19 2007-09-19 富士通株式会社 機能性分子及びその製造方法
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
CA2407825A1 (en) 2002-10-11 2004-04-11 Andrew J. Simmonds Trap-tagging: a novel method for the identification and purification of rna-protein complexes
WO2004063342A2 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP4119976B2 (ja) * 2003-02-07 2008-07-16 国立大学法人群馬大学 5位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1584923A3 (en) 2004-04-07 2006-01-04 Roche Diagnostics GmbH Stabilization of biomolecules in samples
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
JP2006117542A (ja) * 2004-10-19 2006-05-11 Nichirei Biosciences Inc 神経成長因子産生抑制剤、並びにその神経成長因子産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品、痒み予防及び治療剤、及びアトピー性皮膚炎治療剤
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
US7927798B2 (en) 2005-10-05 2011-04-19 Panomics, Inc. Detection of nucleic acids from whole blood
JP5256578B2 (ja) * 2005-12-20 2013-08-07 大正製薬株式会社 掻痒性皮膚疾患の予防または治療剤
PT1994171E (pt) 2006-01-17 2015-07-06 Somalogic Inc Análises multiplexadas de amostras de teste
JP5372737B2 (ja) 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Egfrキナーゼ阻害剤およびegfrキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
EP1897886A1 (en) * 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Compounds as aptamer-dimers and their uses in diagnosis and therapy
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
AU2007337810B2 (en) 2006-12-22 2014-02-13 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US8404830B2 (en) 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2144921A2 (en) * 2007-02-27 2010-01-20 K.U. Leuven Research and Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US20090137506A1 (en) * 2007-05-02 2009-05-28 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CN101809167B (zh) 2007-07-17 2015-04-01 私募蛋白质体公司 产生具有改良的解离速率的适配体的方法
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
KR101694559B1 (ko) 2008-09-24 2017-01-09 가부시키가이샤 리보믹 Ngf에 대한 압타머 및 이의 용도
AU2011223527B2 (en) 2010-03-03 2014-11-13 Somalogic, Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
PL2551346T3 (pl) 2010-03-24 2016-07-29 Ribomic Inc Aptamer dla NGF i jego zastosowanie
SG2014006522A (en) * 2010-04-12 2014-03-28 Somalogic Inc 5-position modified pyrimidines and their use
WO2011130065A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2635681B8 (en) * 2010-11-05 2017-10-04 Miragen Therapeutics, Inc. Base modified oligonucleotides
CN104379764B (zh) * 2012-03-28 2018-04-06 私募蛋白质体公司 Pdgf和vegf的适体及它们在治疗pdgf和vegf介导的病状中的用途
CA2928207A1 (en) 2013-11-21 2015-05-28 Somalogic, Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Also Published As

Publication number Publication date
EA022429B1 (ru) 2015-12-30
SG184089A1 (en) 2012-11-29
EA201291034A1 (ru) 2013-04-30
EP2558478B1 (en) 2018-03-07
IL256013A (en) 2018-05-31
TWI671309B (zh) 2019-09-11
CN102985435B (zh) 2016-10-26
KR20130103317A (ko) 2013-09-23
JP2016145230A (ja) 2016-08-12
JP2013523177A (ja) 2013-06-17
US20130012693A1 (en) 2013-01-10
IL252703A (en) 2017-12-31
JP2013523887A (ja) 2013-06-17
JP6352324B2 (ja) 2018-07-04
EP3345915A1 (en) 2018-07-11
ES2667491T3 (es) 2018-05-11
AR081452A1 (es) 2012-09-05
IL242038A (en) 2017-07-31
IL256014D0 (en) 2018-01-31
IL222339A (en) 2015-11-30
MX2012011779A (es) 2012-12-17
SG2014006522A (en) 2014-03-28
TWI684596B (zh) 2020-02-11
TW201900668A (zh) 2019-01-01
IL242038D0 (en) 2015-11-30
JP6012591B2 (ja) 2016-10-26
TW201936623A (zh) 2019-09-16
IL252703D0 (en) 2017-08-31
EP2558478A1 (en) 2013-02-20
KR20180030229A (ko) 2018-03-21
US20190233461A1 (en) 2019-08-01
CA2793451A1 (en) 2011-10-20
US8598140B2 (en) 2013-12-03
US20180127450A1 (en) 2018-05-10
NO2558478T3 (zh) 2018-08-04
IL222339D0 (en) 2012-12-31
HK1201740A1 (zh) 2015-09-11
TW202019943A (zh) 2020-06-01
TWI643864B (zh) 2018-12-11
CN102858990B (zh) 2016-08-03
KR101842269B1 (ko) 2018-03-26
CN107033204A (zh) 2017-08-11
CA3066785A1 (en) 2011-10-20
SG184497A1 (en) 2012-11-29
CN102985435A (zh) 2013-03-20
TW201629079A (zh) 2016-08-16
KR20130043099A (ko) 2013-04-29
AU2011240677B2 (en) 2015-05-14
TWI505833B (zh) 2015-11-01
EP2558586A1 (en) 2013-02-20
BR112012025872A2 (pt) 2016-10-18
EP2558586B1 (en) 2016-10-12
IL256014A (en) 2018-05-31
IL256013D0 (en) 2018-01-31
DK2558478T3 (en) 2018-05-22
US20150376223A1 (en) 2015-12-31
AU2011240774B2 (en) 2014-04-10
TW201134482A (en) 2011-10-16
US20140058076A1 (en) 2014-02-27
WO2011130195A1 (en) 2011-10-20
KR20190018750A (ko) 2019-02-25
NZ602618A (en) 2013-12-20
WO2011130289A1 (en) 2011-10-20
MX2012011771A (es) 2012-12-17
KR101952671B1 (ko) 2019-02-27
US9163056B2 (en) 2015-10-20
US20110275794A1 (en) 2011-11-10
MY160608A (en) 2017-03-15
US20160355540A1 (en) 2016-12-08
TWI593701B (zh) 2017-08-01
TW201730198A (zh) 2017-09-01
US10221207B2 (en) 2019-03-05
JP2018109050A (ja) 2018-07-12
CA2797188A1 (en) 2011-10-20
EP2558478A4 (en) 2013-10-23
AU2011240774A1 (en) 2012-10-18
CN102858990A (zh) 2013-01-02
CO6630139A2 (es) 2013-03-01
JP5901610B2 (ja) 2016-04-13
ES2610159T3 (es) 2017-04-26
AU2011240677A1 (en) 2012-11-01
CA2797188C (en) 2020-03-31
EP2558586A4 (en) 2014-10-15
CN104069512A (zh) 2014-10-01
UA105290C2 (ru) 2014-04-25

Similar Documents

Publication Publication Date Title
HRP20200549T1 (hr) Određeni amino-pirimidini, njihovi sastavi, i metode njihove upotrebe
HRP20161748T1 (hr) Inhibitori lizinspecifične demetilaze-1 i njihove uporabe
HRP20150858T1 (en) Bromodomain inhibitors and uses thereof
IL250824A (en) Certain amino-pyridazines, compositions thereof, and methods of their use
HK1199725A1 (zh) 雜環化合物及其用途
HK1198443A1 (zh) 雜環化合物及其用途
HK1198475A1 (zh) 雜環化合物及其應用
HK1193561A1 (zh) 雜環化合物和其用途
IL246600A (en) Heterocyclic compounds and uses thereof
HRP20161079T1 (hr) Selektivni inhibitori glikozidaze i njihove uporabe
HK1203493A1 (zh) 取代的氮雜雙環及其用途
HK1192879A1 (zh) 取代的 -苄基環烷基羧酸及其用途
HK1206004A1 (zh) 巨大戟二萜醇- -酰化物 和巨大戟二萜醇- -氨基甲酸酯
IL222176A (en) Radioprotector compounds and methods
HK1225308A1 (zh) 5-氯代-4-羥基-1-甲基-2-氧代基-n-苯基-1,2-二氫喹啉-3-甲酰胺,其鹽和用法
HRP20171189T1 (hr) Bisaril-vezani ariltriazoloni i njihova uporaba
IL249669A (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
IL233051D0 (en) Anti-phf-tau-antibodies and their uses
IL220939D0 (en) Compounds and methods
AP3444A (en) Heteroarylpiperidine and piperazine derivatives asfungicides
IL216973D0 (en) Heterocyclic compounds and their uses
IL222227D0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2542086A4 (en) Compounds and therapeutic uses thereof
IL256013D0 (en) 5-position modified pyrimidines and their use
EP2606031A4 (en) Autotaxin inhibitors and uses thereof